Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Lebanon, NH
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Lebanon, NH
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Albany, NY
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Albany, NY
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Easley, SC
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Easley, SC
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Gaffney, SC
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Gaffney, SC
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Greenville, SC
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Spartanburg, SC
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Union, SC
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Union, SC
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Houston, TX
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
The Woodlands, TX
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
The Woodlands, TX
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Webster, TX
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Webster, TX
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Calgary,
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Calgary,
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Birmingham, AL
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Phoenix, AZ
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Newport Beach, CA
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Torrance, CA
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
DeLand, FL
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
DeLand, FL
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Gainesville, FL
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Gainesville, FL
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Orlando, FL
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Ormond Beach, FL
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Winter Park, FL
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Winter Park, FL
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Duluth, GA
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Duluth, GA
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Coeur d'Alene, ID
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Avon, IN
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Avon, IN
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Lafayette, IN
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Lafayette, IN
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Muncie, IN
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Muncie, IN
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Topeka, KA
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Topeka, KA
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Traverse City, MI
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Traverse City, MI
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Charlotte, NC
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Shelby, NC
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Shelby, NC
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Winston-Salem, NC
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Columbus, OH
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Oklahoma City, OK
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Medford, OR
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Medford, OR
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Easley, SC
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Easley, SC
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Easley, SC
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Easley, SC
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Fort Mill, SC
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Fort Mill, SC
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Gaffney, SC
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Gaffney, SC
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Greenville, SC
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Rock Hill, SC
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Rock Hill, SC
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Seneca, SC
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Seneca, SC
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Spartanburg, SC
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Union, SC
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Union, SC
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Johnson City, TN
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Johnson City, TN
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Edinburg, TX
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Edinburg, TX
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Abingdon, VA
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Abingdon, VA
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Saint Charles, MO
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Saint Charles, MO
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Saint Louis, MO
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Elsterwerda,
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Elsterwerda,
Click here to add this to my saved trials
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Cincinnati, OH
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials